Key facts
- Precision Neuroscience’s last known valuation is $529.0M (Oct 2024).
- It has raised $179.1M across 4 recorded rounds; the latest was Later Stage VC ($93.1M) in Oct 2024.
- Notable investors include Alumni Ventures, Draper Associates, Korea Investment Partners, B Capital Group, Chestnut Street Ventures — 17 tracked in total.
- Precision Neuroscience has filed 5 Form Ds with the SEC since 2021, most recently Oct 2024 ($93.1M sold to 21 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Precision Neuroscience
Funding rounds
4 roundsAbout Precision Neuroscience
Developer of a brain-computer interface device technology designed to provide effective treatment for patients with neurological illnesses. The company's thin-film microelectrode array conforms to the brain surface without penetrating tissue, collecting and processing large amounts of neural data across multiple brain regions, enabling medical providers to treat conditions such as spinal cord injuries, stroke, and neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Employees
- 115
- Website
- precisionneuro.io/
- Ownership
- Privately Held (backing)
Precision Neuroscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Precision Neuroscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Precision Neuroscience in its N-PORT filings yet. We sweep new filings monthly.